<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0034-7523</journal-id>
<journal-title><![CDATA[Revista Cubana de Medicina]]></journal-title>
<abbrev-journal-title><![CDATA[Rev cubana med]]></abbrev-journal-title>
<issn>0034-7523</issn>
<publisher>
<publisher-name><![CDATA[Centro Nacional de Información de Ciencias MédicasEditorial Ciencias Médicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0034-75232021000500007</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Cardiotoxicidad inducida por trastuzumab en paciente con carcinoma de mama HER-2 positivo]]></article-title>
<article-title xml:lang="en"><![CDATA[Trastuzumab-induced cardiotoxicity in a patient with HER-2 positive breast carcinoma]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Carballo Torres]]></surname>
<given-names><![CDATA[Daniel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lima Pérez]]></surname>
<given-names><![CDATA[Mayte]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Luperón Loforte]]></surname>
<given-names><![CDATA[Daysi]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Concepción]]></surname>
<given-names><![CDATA[Iván Ramón]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Clínico Quirúrgico &#8220;Hermanos Ameijeiras&#8221;  ]]></institution>
<addr-line><![CDATA[ La Habana]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2021</year>
</pub-date>
<volume>60</volume>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S0034-75232021000500007&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S0034-75232021000500007&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S0034-75232021000500007&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  La disfunción cardíaca emerge como una de las principales causas de morbilidad y mortalidad entre los sobrevivientes de cáncer. En la actualidad, el trastuzumab se considera parte de la terapia estándar para el cáncer de mama; sin embargo, se asocia a una variada incidencia de cardiotoxicidad.  Caso clínico:  Paciente femenina de 52 años que recibió neoadyuvancia con antraciclinas, y luego, taxanos combinados a trastuzumab. Se le realizó una cuadrantectomía de mama izquierda por un carcinoma ducto lobulillar infiltrante, etapa IIIa, con un fenotipo: luminal B- Her2 positivo. Desarrolló una insuficiencia cardiaca congestiva, luego de dos dosis de trastuzumab posoperatorio. La fracción de eyección ventricular izquierda descendió de 65 % (previo al tratamiento con antraciclinas) a 44 %. Recibió tratamiento con enalapril, carvedilol, y espironolactona. Se recuperó la fracción de eyección ventricular izquierda a 57 %, por lo que se reintrodujo el trastuzumab y así completar las 18 dosis planificadas, luego de cuatro meses de suspensión. Actualmente, está libre de enfermedad, en tratamiento hormonal con letrozol y sin síntomas cardiovasculares.  Conclusiones:  La cardiotoxicidad por trastuzumab puede ser reversible, si se trata adecuada y oportunamente, en el marco de grupos multidisciplinarios y Unidades de Cardio-Oncología.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  Cardiac dysfunction emerges as one of the main causes of morbidity and mortality among cancer survivors. Currently, trastuzumab is considered part of the standard therapy for breast cancer; however, it is associated with a varied incidence of cardiotoxicity.  Clinical case report:  A case of a 52-year-old female patient is reported here, because she received neoadjuvant therapy with anthracyclines and later, taxanes combined with trastuzumab. She underwent a quadrantectomy of her left breast for an infiltrating lobular duct carcinoma, stage IIIa, with a phenotype: luminal B-Her2 positive. She developed congestive heart failure after two doses of postoperative trastuzumab. The left ventricular ejection fraction decreased from 65% (prior to anthracycline treatment) to 44%. She was treated with enalapril, carvedilol, and spironolactone. The left ventricular ejection fraction was recovered to 57%, so trastuzumab was reintroduced and thus complete the 18 planned doses, after four months of suspension. Currently, she is disease-free, on hormonal treatment with letrozole, and without cardiovascular symptoms.  Conclusions:  Cardiotoxicity due to trastuzumab can be reversible, if it is appropriately and timely treated, within the framework of multidisciplinary groups and Cardio-Oncology Units.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[trastuzumab]]></kwd>
<kwd lng="es"><![CDATA[cardiotoxicidad]]></kwd>
<kwd lng="es"><![CDATA[disfunción ventricular]]></kwd>
<kwd lng="en"><![CDATA[trastuzumab]]></kwd>
<kwd lng="en"><![CDATA[cardiotoxicity]]></kwd>
<kwd lng="en"><![CDATA[ventricular dysfunction]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[CB]]></given-names>
</name>
<name>
<surname><![CDATA[Davis]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
<name>
<surname><![CDATA[Law]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Suplher]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Shared risk factors for cardiovascular disease and cancer Implications for preventive health and clinical care in oncology patients]]></article-title>
<source><![CDATA[Can J Cardiol]]></source>
<year>2016</year>
<volume>32</volume>
<page-range>900-7</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Curigliano]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Cardinale]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Dent]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Criscitiello]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Aseyev]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Lenihan]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiotoxicity of anticancer treatments epidemiology, detection, and management]]></article-title>
<source><![CDATA[CA Cancer J Clin]]></source>
<year>2016</year>
<volume>66</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>309-25</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harbeck]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Gnant]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Breast cancer]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2017</year>
<volume>389</volume>
<page-range>1134-50</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hsu]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Hung]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer]]></article-title>
<source><![CDATA[Cancer Metastasis Rev]]></source>
<year>2016</year>
<volume>35</volume>
<page-range>575-88</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Han]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Precision cardio-oncology understanding the cardiotoxicity of cancer therapy]]></article-title>
<source><![CDATA[NPJ Precis Oncol]]></source>
<year>2017</year>
<volume>1</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>31</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moilanen]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Jokimäki]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Tenhunen]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Koivunen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Trastuzumab-induced cardiotoxicity and its risk factors in real-world setting of breast cancer patients]]></article-title>
<source><![CDATA[J Cancer Res Clin Oncol]]></source>
<year>2018</year>
<volume>144</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1613-21</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="">
<collab>American Joint Committee on Cancer</collab>
<source><![CDATA[Updated breast chapter for eighth edition]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Soriano]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Montejo]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Batista]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Loys]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lima]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Castillo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cáncer de mama en estadios tempranos]]></article-title>
<source><![CDATA[Manual de Prácticas Médicas IV Edición. Unidad Funcional de Tumores]]></source>
<year>2012</year>
<page-range>54</page-range><publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[Ed. Ciencias Médicas]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Truong]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Yan]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
<name>
<surname><![CDATA[Cramarossa]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Chemotherapy-induced cardiotoxicity detection, prevention and management]]></article-title>
<source><![CDATA[Can J Cardiol]]></source>
<year>2014</year>
<volume>30</volume>
<page-range>869-78</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kalam]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Otahal]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Marwick]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic implications of global LV dysfunction a systematic review and meta-analysis of global longitudinal strain and ejection fraction]]></article-title>
<source><![CDATA[Heart]]></source>
<year>2014</year>
<volume>100</volume>
<numero>21</numero>
<issue>21</issue>
<page-range>1673-80</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Negishi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Thavendiranathan]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Negishi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Marwick]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rationale and design of the strain surveillance of chemotherapy for improving cardiovascular outcomes the SUCCOUR trial]]></article-title>
<source><![CDATA[JACC Cardiovasc Imaging]]></source>
<year>2018</year>
<volume>11</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1098-05</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Janbabai]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Nabati]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Faghihinia]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Azizi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Borhani]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Yazdani]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of enalapril on preventing anthracycline-induced cardiomyopathy]]></article-title>
<source><![CDATA[Cardiovasc Toxicol]]></source>
<year>2017</year>
<volume>17</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>130-9</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Florio]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Alvarez]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Gálvez]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rol cardioprotector del carvedilol para pacientes en quimioterapia, revisión sistemática y metanálisis de estudios clínicos aleatorizados]]></article-title>
<source><![CDATA[Horiz Med]]></source>
<year>2018</year>
<volume>18</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>48-58</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Manrique]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Spinetto]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Tiwari]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Romero]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jorde]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Garcia]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Protective effect of beta-blockers on chemotherapy induced cardiomyopathy a meta-analysis of prospective studies]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2016</year>
<volume>67</volume>
<numero>13^sSuppl</numero>
<issue>13^sSuppl</issue>
<supplement>Suppl</supplement>
<page-range>1529</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López Fernández]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Martín García]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Santaballa]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Montero]]></surname>
<given-names><![CDATA[Á]]></given-names>
</name>
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Mazón]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardio-Onco-Hematología en la práctica clínica documento de consenso y recomendaciones]]></article-title>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2017</year>
<volume>70</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>474-86</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
